文章摘要
尹佳钰,吕欣妮,钱丽君,等.基于CiteSpace的中医药治疗化疗后白细胞减少可视化分析[J].浙江中医药大学学报,2023,47(2):190-197, 202.
基于CiteSpace的中医药治疗化疗后白细胞减少可视化分析
Visualization Analysis of Leukopenia after Chemotherapy in TCM Based on CiteSpace
DOI:10.16466/j.issn1005-5509.2023.02.015
中文关键词: 化疗  白细胞减少  中医药  CiteSpace  可视化分析  科学知识图谱
英文关键词: chemotherapy  leukopenia  traditional Chinese medicine  CiteSpace  visualization analysis  scientific knowledge graph
基金项目:江苏省重点研发(社会发展)计划(BE2021753)
作者单位
尹佳钰 南京中医药大学附属中西医结合医院 南京 210028 
吕欣妮 南京中医药大学附属中西医结合医院 南京 210028 
钱丽君 南京中医药大学附属中西医结合医院 南京 210028 
金梦洁 南京中医药大学附属中西医结合医院 南京 210028 
张振生 南京中医药大学附属中西医结合医院 南京 210028 
方志军 南京中医药大学附属中西医结合医院 南京 210028
江苏省中医药研究院 
摘要点击次数: 1210
全文下载次数: 501
中文摘要:
      [目的] 探究中医药治疗化疗后白细胞减少的研究现状、热点及前沿趋势。[方法] 检索2001年1月1日至2021年12月31日中国知网(China National Knowledge Infrastructure,CNKI)中关于中医药治疗化疗后白细胞减少的相关文献,采用CiteSpace 5.8.R3软件绘制作者及机构的合作网络图谱,
英文摘要:
      [Objective] To explore the research status, hot spots and frontier trends of traditional Chinese medicine(TCM) treatment of leukopenia after chemotherapy. [Methods] The literature related to the treatment of leukopenia after chemotherapy by TCM was retrieved from China National Knowledge Infrastructure(CNKI) from January 1, 2001 to December 31, 2021, CiteSpace 5.8.R3 software was used to draw the collaborative network graph of authors and institutions, and Keywords co-occurrence, clustering, time line and emergent view. [Results] A total of 442 papers were included, and there were three close collaboration groups: ZHANG Xiping, LIU Bo and ZHANG Ying. There was less inter-agency cooperation, but there was a small number of cross-agency and cross-regional cooperation. The hot Keywords were clinical efficacy, Shengbai Decoction, breast cancer, cyclophosphamide, etc. The 10 clusters could be divided into 4 groups: clinical research of TCM, syndrome differentiation and treatment of TCM, mechanism research, Chinese drug research and medication rule. In recent 20 years, TCM syndrome differentiation and treatment had always been the focus and hotspot of clinical research. Since 2013, the focus of research had gradually shifted from simple internal administration of TCM to treatment with characteristic technology of TCM. Since 2019, studies had focused on cyclophosphamide, omics and other mechanisms. [Conclusion] The research focuses for treatment of leukopenia after chemotherapy are divided into three aspects: TCM syndrome differentiation and treatment, TCM characteristic treatment and research on highly related cancer species. The frontier trends are divided into immunological function and multiomics research on leukopenia induced by chemotherapeutic drugs represented by cyclophosphamide, and study on the law and mechanism of TCM. The field of TCM treatment of leukopenia after chemotherapy has a good development prospect, but attention is not enough, research needs to be in-depth, and exchanges and cooperation need to be strengthened.
查看全文   查看/发表评论  下载PDF阅读器
关闭